Posted by Michael Wonder on 13 Jun 2020
ZZ Biotech announces FDA fast track designation for stroke program
12 June 2020 - ZZ Biotech today announced that the US FDA has designated the investigation of the company’s experimental drug 3K3A-APC for the treatment of acute ischaemic stroke as a fast track development program.
ZZ Biotech’s 3K3A-APC is a genetically engineered variant of the naturally occurring activated Protein C, which plays a role in the regulation of blood clotting and inflammation.
In animal models of stroke, 3K3A-APC has helped prevent bleeding caused by tPA, the only drug currently indicated for the treatment of acute ischaemic stroke.
